The first and only treatment of its kind approved for metastatic prostate cancer that is hormone sensitive (mHSPC) when used in combination with docetaxel
NUBEQA® (darolutamide) is a prescription medicine used to treat adults with prostate cancer that has spread to other parts of the body and responds to medical or surgical treatment that lowers testosterone; NUBEQA is used in combination with docetaxel.
It is not known if NUBEQA is safe and effective in women and children.
SEE HOW NUBEQA
MAY HELP YOU
LIVE LIFE LONGER AND
GIVE YOU MORE TIME
WITHOUT PAIN PROGRESSION
Explore the clinical results below to see how NUBEQA in addition to chemotherapy* and hormone therapy† helped men with mHSPC.
*Docetaxel.
†Hormone therapy includes GnRH, such as Lupron Depot® (drug treatment), or surgery that lowers testosterone.
The NUBEQA combination allows
you to fight mHSPC 3 ways at once
NUBEQA is:
- the first and only treatment of its kind approved for mHSPC in combination with docetaxel
- a twice-daily, oral prescription medicine that blocks testosterone, which helps delay cancer cell growth
†Hormone therapy includes GnRH, such as Lupron Depot® (drug treatment), or surgery that lowers testosterone.
CLINICALLY PROVEN
IN MEN WITH mHSPC
In a clinical trial of 1305 men with mHSPC:
- 651 men received the NUBEQA combination
- Patients who were given the NUBEQA combination in the clinical trial received chemotherapy* for 6 cycles (approximately 4 months) and continued receiving NUBEQA and hormone therapy† until their doctor stopped their treatment
- 654 men received chemotherapy* + hormone therapy† alone
- Patients received chemotherapy* for 6 cycles (approximately 4 months) and continued receiving hormone therapy† until their doctor stopped their treatment
- Chemotherapy* + hormone therapy† is a guideline-recommended therapy in mHSPC
- The study measured overall survival (OS), which is the length of time a person may live after starting therapy
- The study also measured:
- Length of time before disease progressed to mCRPC
- Length of time before pain progressed
Talk to your doctor to learn more.
*Docetaxel.
†Hormone therapy includes GnRH, such as Lupron Depot® (drug treatment), or surgery that lowers testosterone.
In the clinical trial,
MEN LIVED LONGER WITH NUBEQA
At 4 years of treatment in the clinical study:
- More men who received the NUBEQA combination were still alive (63% compared with 50% of the men who received chemotherapy* + hormone therapy†)
- The NUBEQA combination extended overall survival by lowering the risk of death by 32%
NUBEQA helps you live for what you love
MORE TIME WITHOUT PAIN PROGRESSION
At 4 years of treatment in the clinical study:
- NUBEQA lowered the risk of time to pain progression by 21%
*Docetaxel.
†Hormone therapy includes GnRH, such as Lupron Depot® (drug treatment), or surgery that lowers testosterone.
COMMON SIDE EFFECTS
The most common side effects of NUBEQA when used in combination with docetaxel in people with mHSPC include:
- Constipation
- Decreased appetite
- Rash
- Bleeding
- Weight gain
- High blood pressure
- Decreased red blood cells (anemia)
- High blood sugar levels
- Decreased white blood cells
- Increase in liver function tests
- Low blood calcium levels
Ask your doctor if NUBEQA is right for you
Talk to your doctor about the clinical study results published in the